<DOC>
	<DOCNO>NCT03036488</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pembrolizumab ( MK-3475 ) plus chemotherapy v placebo plus chemotherapy neoadjuvant therapy pembrolizumab v placebo adjuvant therapy participant triple negative breast cancer ( TNBC ) . After screen phase approximately 28 day , participant receive neoadjuvant study treatment ( Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy ) base randomization schedule approximately 24 week ( 8 cycle ) . Each participant undergo definitive surgery 3-6 week conclusion last cycle neoadjuvant study treatment . After definitive surgery , participant receive adjuvant study treatment ( Pembrolizumab OR Placebo ) approximately 27 week ( 9 cycle ) . Following adjuvant study treatment , participant monitor safety , survival disease recurrence . The primary study hypothesis pembrolizumab superior placebo , combination chemotherapy , measure rate Pathological Complete Response ( pCR ) and/or Event-free Survival ( EFS ) , participant locally advance TNBC .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Plus Chemotherapy v Placebo Plus Chemotherapy Neoadjuvant Therapy Pembrolizumab v Placebo Adjuvant Therapy Participants With Triple Negative Breast Cancer ( TNBC ) ( MK-3475-522/KEYNOTE-522 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Has newly diagnose , locally advanced , centrally confirm TNBC , define recent American Society Clinical Oncology ( ASCO ) /College American Pathologists ( CAP ) guideline . Has previously untreated locally advanced nonmetastatic ( M0 ) TNBC define follow combined primary tumor ( T ) regional lymph node ( N ) stag per American Joint Committee Cancer ( AJCC ) Breast Cancer Staging Version 7 assess investigator base radiological and/or clinical assessment : T1c , N1N2 T2 , N0N2 T3 , N0N2 T4ad , N0N2 Provides core needle biopsy consist least 2 separate tumor core primary tumor screen central laboratory . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 perform within 10 day treatment initiation . Demonstrates adequate organ function . Males female participant childbearing potential must willing use adequate method contraception course study 12 month last dose study treatment participant receive cyclophosphamide , 6 month last dose study treatment participant . Has history invasive malignancy â‰¤5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Has receive prior chemotherapy , target therapy , radiation therapy within past 12 month . Has receive prior therapy antiprogrammed cell death protein 1 ( antiPD1 ) , antiprogrammed death ligand 1 ( antiPDL1 ) , antiPDL2 agent agent direct another coinhibitory Tcell receptor ( e.g. , cytotoxic Tlymphocyteassociated antigen4 [ CTLA4 ] , OX40 , CD137 [ tumor necrosis factor receptor superfamily member 9 ( TNFRSF9 ) ] ) previously participate pembrolizumab ( MK3475 ) clinical study . Is currently participate participate interventional clinical study investigational compound device within 4 week first dose treatment current study . Has receive live vaccine within 30 day first dose study treatment . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C. Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has active infection require systemic therapy . Has significant cardiovascular disease , : history myocardial infarction , acute coronary syndrome coronary angioplasty/stenting/bypass graft within last 6 month OR congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class IIIV history CHF NYHA Class III IV . Is pregnant breastfeeding , expect conceive child within project duration study , start screen visit 12 month last dose study treatment participant receive cyclophosphamide , 6 month last dose study treatment participant . Has know hypersensitivity component study treatment analog . Has know history active tuberculosis ( TB , Bacillus Tuberculosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>